---
layout: post
title: "益盛药业产品人参和生脉注射液列入新冠肺炎诊疗方案（试行第九版）"
date: 2022-03-17 17:51:22 +0800
categories: shanghaizhengquanbao·zhongguozhengquanwang
tags: 上海证券报·中国证券网新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.002566" data-code="002566|0|2" data-code2="002566|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002566&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002566_0" data-code="K 002566|0|2" data-code2="K 002566|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>益盛药业公告，近日，国家卫生健康委员会和国家中医药管理局联合发布了《新型冠状病毒肺炎诊疗方案(试行第九版)》，公司产品人参和生脉注射液列入临床治疗期(确诊病例)危重型推荐处方及推荐中成药。<br /></p><p class="em_media">（文章来源：上海证券报·中国证券网）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202203172314093010>

[返回上海证券报·中国证券网新闻](//finews.withounder.com/category/shanghaizhengquanbao·zhongguozhengquanwang.html)｜[返回首页](//finews.withounder.com/)